PL417544A1 - Method for modification of polypeptide sequence and its application - Google Patents

Method for modification of polypeptide sequence and its application

Info

Publication number
PL417544A1
PL417544A1 PL417544A PL41754416A PL417544A1 PL 417544 A1 PL417544 A1 PL 417544A1 PL 417544 A PL417544 A PL 417544A PL 41754416 A PL41754416 A PL 41754416A PL 417544 A1 PL417544 A1 PL 417544A1
Authority
PL
Poland
Prior art keywords
application
modification
polypeptide sequence
subject
modified
Prior art date
Application number
PL417544A
Other languages
Polish (pl)
Other versions
PL238516B1 (en
Inventor
Mateusz Krzyścik
Michał Łobocki
Aleksandra Sokołowska-Wędzina
Aleksandra Borek
Alicja Sochaj-Gregorczyk
Piotr Jakimowicz
Małgorzata Zakrzewska
Daniel Krowarsch
Jacek Otlewski
Original Assignee
Uniwersytet Wrocławski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Wrocławski filed Critical Uniwersytet Wrocławski
Priority to PL417544A priority Critical patent/PL238516B1/en
Priority to EP16831758.4A priority patent/EP3468611A1/en
Priority to PCT/IB2016/058083 priority patent/WO2017216620A1/en
Publication of PL417544A1 publication Critical patent/PL417544A1/en
Publication of PL238516B1 publication Critical patent/PL238516B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Przedmiotem zgłoszenia jest sposób modyfikacji polipeptydów, polegający na wprowadzeniu specyficznej sekwencji aminokwasowej (łącznika) do sekwencji aminokwasowej polipeptydu. Przedmiotem zgłoszenia jest też łącznik, który zawiera wysoce reaktywną resztę cysterny, którą można modyfikować powszechnie stosowanymi odczynnikami. Tak zmodyfikowane białko może służyć jako nośnik leku.The subject of the application is a method of modification of polypeptides, consisting in introducing a specific amino acid sequence (linker) into the amino acid sequence of a polypeptide. The subject of the application is also a connector which contains a highly reactive tanker residue that can be modified with commonly used reagents. The protein thus modified can serve as a carrier for the drug.

PL417544A 2016-06-13 2016-06-13 Method for obtaining a modified polypeptide PL238516B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL417544A PL238516B1 (en) 2016-06-13 2016-06-13 Method for obtaining a modified polypeptide
EP16831758.4A EP3468611A1 (en) 2016-06-13 2016-12-29 Human fibroblast growth factor 2 (fgf2) - cytotoxic drug conjugates for targeted therapy of fgfr-related cancers
PCT/IB2016/058083 WO2017216620A1 (en) 2016-06-13 2016-12-29 Human fibroblast growth factor 2 (fgf2) - cytotoxic drug conjugates for targeted therapy of fgfr-related cancers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL417544A PL238516B1 (en) 2016-06-13 2016-06-13 Method for obtaining a modified polypeptide

Publications (2)

Publication Number Publication Date
PL417544A1 true PL417544A1 (en) 2017-12-18
PL238516B1 PL238516B1 (en) 2021-08-30

Family

ID=57915022

Family Applications (1)

Application Number Title Priority Date Filing Date
PL417544A PL238516B1 (en) 2016-06-13 2016-06-13 Method for obtaining a modified polypeptide

Country Status (3)

Country Link
EP (1) EP3468611A1 (en)
PL (1) PL238516B1 (en)
WO (1) WO2017216620A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020080656A1 (en) * 2018-10-15 2020-04-23 국립암센터 Fgf2 or api5 derived peptide and use thereof
KR102241134B1 (en) * 2019-08-08 2021-04-16 국립암센터 Oncolytic virus for expressing peptide derived from FGF2 or API5 and uses thereof
US12403179B2 (en) 2021-02-18 2025-09-02 The Board Of Trustees Of The University Of Arkansas Release of growth factors at wound healing stages
CN116650679A (en) * 2023-04-14 2023-08-29 河北医科大学第四医院 Image probe for targeting FGFR1 and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859208A (en) * 1988-07-06 1999-01-12 Fiddes; John C. Human basic fibroblast growth factor analog
CA2089820C (en) * 1990-09-19 1999-01-19 Paul Calabresi Treatment of tumorigenic pathophysiological conditions with fgf-cytotoxic conjugates
CA2168647A1 (en) * 1993-08-02 1995-02-09 Barbara A. Sosnowski Monogenous preparations of cytotoxic conjugates
BRPI0912035A2 (en) 2008-05-29 2017-05-23 Galaxy Biotech Llc monoclonal antibody, pharmaceutical composition, use of a pharmaceutical composition, mouse mab in chimeric or humanized form, and humanized antibody
US8481688B2 (en) 2010-05-11 2013-07-09 Aveo Pharmaceuticals, Inc. Anti-FGFR2 antibodies
WO2014179448A2 (en) 2013-05-01 2014-11-06 Five Prime Therapeutics, Inc. Methods of treating cancer

Also Published As

Publication number Publication date
EP3468611A1 (en) 2019-04-17
WO2017216620A1 (en) 2017-12-21
PL238516B1 (en) 2021-08-30

Similar Documents

Publication Publication Date Title
MX2016008355A (en) Antibodies comprising c-terminal light chain polypeptide extensions and conjugates and methods of use thereof.
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
PE20191463A1 (en) BISPECIFIC ANTIBODIES OF SPECIFIC JOINT PD1 AND LAG3
PH12020550240A1 (en) D-domain containing polypeptides and uses thereof
EP4614155A3 (en) Methods of assaying proteins
PE20181923A1 (en) NEOANTIGENS AND METHODS OF THEIR USE
GB2569252A (en) Methods of combining the detection of biomolecules into a single assay using fluorescent in situ sequencing
MX2018013762A (en) Cd40l-fc fusion polypeptides and methods of use thereof.
PE20170665A1 (en) HUMANIZED ANTI-TAU ANTIBODIES
MX2021000030A (en) Methods and compositions using klotho variant polypeptides.
MY206284A (en) Anti-cd63 antibodies, conjugates, and uses thereof
MX2022008013A (en) Stabilization of fc-containing polypeptides.
MY187827A (en) New polypeptide having affinity to pd-l1
CO6231038A2 (en) UNION PROTEINS, INCLUDING ANTIBODIES DERIVED FROM ANTIBODY AND ANTIBODY FRAGMENTS THAT SPECIFICALLY JOIN CD154 AND ITS USES
MX2020003260A (en) Fc-receptor binding modified asymmetric antibodies and methods of use.
MX2017006866A (en) UNION COUPLE FOR PRODUCTION OF PEPTIDES.
MX2017000083A (en) Platinum compounds, compositions, and uses thereof.
EA201892325A1 (en) COMPOSITIONS AND METHODS OF DETECTING PROTEINS OF CELL-HOST
SG10201903142RA (en) Serpin fusion polypeptides and methods of use thereof
WO2015006337A3 (en) Compositions and methods for increasing protein half-life in a serum
MX2017010359A (en) Fc-FUSED HIGH AFFINITY IgE RECEPTOR a-CHAIN.
SG11201907866SA (en) Horseshoe crab factor b variant
TW201613981A (en) Compositions and methods for the diagnosis of rheumatoid arthritis
MX2016010623A (en) ANTIBODY TO FOLLOW SEX PROPORTIONS AND METHODS OF USE OF THE SAME.
WO2014160273A3 (en) Protein standard